Two Sigma Advisers
GLMD icon

Two Sigma Advisers’s Galmed Pharmaceuticals GLMD Stock Holding History

Two Sigma Advisers’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-31,491
Closed -$23.6K – 875
2025
Q4 		$23.6K Buy
+31,491
New +$36.8K ﹤0.01% 2308
2024
Q2 		– Sell
-1,856
Closed -$7.71K – 2533
2024
Q1 		$7.71K Sell
1,856
-1,847
-50% -$8.32K ﹤0.01% 2421
2023
Q4 		$20.2K Sell
3,703
-516
-12% -$2.46K ﹤0.01% 2450
2023
Q3 		$31.4K Buy
+4,219
New +$56K ﹤0.01% 2304
2021
Q3 		– Sell
-84
Closed -$46K – 2519
2021
Q2 		$46K Sell
84
-13
-13% -$7.07K ﹤0.01% 2386
2021
Q1 		$60K Buy
+97
New +$67.1K ﹤0.01% 2488

Other funds holding GLMD

Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Two Sigma Advisers's GLMD Position: Q1 2026 in Review

Two Sigma Advisers sold out of Galmed Pharmaceuticals (GLMD) in Q1 2026, closing a stake of 31,491 shares — an estimated $23.6K sold.

Two Sigma Advisers first reported a position in GLMD in Q1 2021 and held it in 6 quarters. The position peaked at $60K in Q1 2021. 16 funds tracked by Wall St. Rank hold GLMD as of Q1 2026.

  • Two Sigma Advisers reported no remaining Galmed Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 31,491 Galmed Pharmaceuticals shares in Q1 2026, an estimated $23.6K.
  • Two Sigma Advisers first reported a position in Galmed Pharmaceuticals in Q1 2021 and held it in 6 quarters.
  • Two Sigma Advisers's Galmed Pharmaceuticals position peaked at $60K in Q1 2021.
  • 16 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.